Mucosis

Mucosis B.V.
Meditech Center
L.J. Zielstraweg 1
9713 GX Groningen
The Netherlands

Trade Register / KvK: 02096219

 

Strategy

We develop vaccines that address currently unmet medical needs. Our competitive edge comes from our proprietary Mimopath™ technology, which facilitates needle-free administration of vaccines into the nose, which raises a more natural immune response and provides a broader base of protection. Our initial focus is on the development of nasal vaccines based on an improved formulation of existing (marketed) vaccines. Since it is established how such vaccines can be developed and how they provide protection, the development risks and costs of such vaccines are significantly reduced, and time to market is shortened.